The Swiss economic consulting company Prognos conducted in 2018 an analysis of the direct savings and the potential direct savings for the German market. They were calculated for the years 2015-2018, and they ranged between €202 and €206 million per year throughout the period. The largest amount of savings was found in the group of medicines that fulfilled the quota, i.e. those with a price difference at least 15% or 15 euro measured on the reimbursement price of the parallel import and the corresponding original product.